쇼트리드 시퀀싱 시장 : 제품별, 기술별, 최종 사용자별, 용도별 - 시장 예측(2026-2032년)

The Short-read Sequencing Market was valued at USD 7.84 billion in 2025 and is projected to grow to USD 9.15 billion in 2026, with a CAGR of 16.42%, reaching USD 22.76 billion by 2032.

A strategic introduction highlighting the operational and scientific relevance of short-read sequencing across research, diagnostics, and commercial applications

Short-read sequencing has matured from a disruptive laboratory technique into a foundational capability that underpins modern molecular biology, clinical diagnostics, and industrial biotechnology. Advances in chemistry, instrumentation, and data processing have pushed throughput, accuracy, and cost-efficiency to levels that enable routine deployment across research, clinical, and commercial environments. As a result, stakeholders ranging from academic laboratories to large pharmaceutical companies are rethinking workflows, partnering models, and capital allocation to integrate sequencing-driven insights into core operations.

This introduction frames the strategic importance of short-read platforms by linking recent technological improvements to practical outcomes. Short-read approaches continue to offer high per-base accuracy, established bioinformatics ecosystems, and relative affordability for targeted and whole-genome assays. Consequently, they remain the preferred option for many standard applications even as long-read technologies gain traction in niche areas. Throughout this document, we adopt a lens that balances technical nuance with operational relevance, emphasizing how iterative improvements in reagents, instrumentation, and analytics combine to reshape decision-making horizons.

Through this perspective, readers will gain an understanding of where short-read sequencing delivers the greatest incremental value, how adoption patterns differ by user profile, and which strategic responses are most effective for organizations seeking to leverage sequencing as a competitive advantage. The following sections unpack the transformative shifts, policy impacts, segmentation logic, regional distinctions, leading corporate behaviors, actionable recommendations, and the research methodology that together support robust decision-making.

How rapid technological refinements, software democratization, and evolving service models are reshaping short-read sequencing adoption and value delivery

The landscape of short-read sequencing is experiencing transformative shifts driven by converging technological, regulatory, and market forces. Chemistry and instrument refinements have steadily improved read accuracy, reduced run-to-run variability, and simplified sample preparation, which collectively lower barriers to adoption in decentralized settings. Parallel advances in library preparation kits and flow cell design have shortened time-to-answer and enabled faster turnaround in clinical workflows, reinforcing sequencing's role in time-sensitive diagnostics.

At the same time, software innovations and cloud-native bioinformatics pipelines are democratizing access to advanced analysis, allowing smaller laboratories to apply complex variant calling, transcript quantification, and metagenomic profiling. Interoperability and standardized data formats are facilitating collaborative research and multi-center studies. Meanwhile, the competitive dynamic among instrument and reagent providers is accelerating product development cycles and expanding service offerings such as integrated sample-to-insight platforms.

Regulatory and reimbursement environments are also evolving; stricter validation requirements coexist with clearer pathways for diagnostic approval, which incentivizes vendors to invest in robust clinical utilities. Supply chain optimization and modular business models, including instrument-as-a-service and reagent subscriptions, are reshaping customer relationships. In short, the short-read sequencing ecosystem is shifting toward greater accessibility, higher integration, and more diverse commercialization models that collectively broaden its impact across scientific and clinical domains.

Assessing how United States tariff changes for 2025 are driving supply chain resilience, sourcing shifts, and procurement strategies across the sequencing ecosystem

The imposition of new tariffs and trade measures in the United States for 2025 has introduced a material compliance and cost-management dimension for organizations that rely on imported reagents, consumables, and instrumentation. These policy changes have prompted procurement teams and suppliers to reassess sourcing strategies, consider alternative logistics pathways, and evaluate nearshoring or regional distribution partnerships to mitigate exposure to tariff-driven price variability. As companies adjust, they increasingly emphasize contractual flexibility, multi-supplier qualification, and inventory management to sustain operational continuity.

In response to tariff pressures, some manufacturers have accelerated localization of production for high-volume consumables and critical components, while service providers have explored value-added logistics solutions to shield end users from sudden cost shifts. Regulatory scrutiny of supply chains has also risen, prompting enhanced documentation, supplier audits, and traceability measures that extend the timeline and complexity of vendor qualification processes. Consequently, capital planning cycles for laboratories and clinical adopters now account for potential tariff-related schedule and cost deviations.

Looking forward, the tariffs have catalyzed broader conversations about supply chain resilience, procurement governance, and strategic inventory posture. Organizations that proactively diversify supplier bases, engage in forward purchasing where appropriate, and collaborate with vendors on localized production and consignment models are better positioned to maintain consistent access to sequencing reagents and instruments while preserving budget predictability.

Integrated segmentation insights revealing how product types, sequencing technologies, user profiles, and application modalities together shape adoption and value chains

Understanding market dynamics requires a clear view of how products, technologies, end users, and applications intersect to shape demand and adoption patterns. Based on product, the market is examined across Consumables, Instruments, and Software & Services with Consumables further segmented into Flow Cells & Reagents and Library Prep Kits, Instruments separated into Benchtop Sequencers and High-Throughput Sequencers, and Software & Services divided into Bioinformatics Services and Data Analysis Software. This product-level framing reveals that procedural dependencies and recurring reagent consumption drive recurring revenue models, while instrument capital expenditure decisions hinge on throughput, footprint, and integration capability.

Based on technology, the landscape is charted across Semiconductor Sequencing, Sequencing Ligation, and Sequencing Synthesis, with Semiconductor Sequencing further characterized by platforms such as Ion Proton and Ion Torrent PGM. Each technology presents distinct trade-offs in read length, throughput, and run economics, which influence suitability for specific applications. Based on end user, the market encompasses Academic & Research Institutes, Contract Research Organizations, Hospitals & Diagnostic Labs, and Pharma & Biotech Companies, and this segmentation clarifies how purchasing cycles, validation demands, and service expectations vary across institutions.

Based on application, the analysis addresses Epigenomics, Genomics, Metagenomics, and Transcriptomics, further detailing Epigenomics into Chromatin Accessibility Analysis and DNA Methylation Analysis, and Genomics into Resequencing, Targeted Sequencing, and Whole Genome Sequencing. This application-focused perspective underscores how analytical priorities-such as depth versus breadth of coverage, sensitivity for rare variants, and throughput-determine the optimal constellation of products and services for a given use case. Integrating these segmentation lenses enables more precise market positioning, technology roadmapping, and customer engagement strategies.

Regional dynamics and policy environments explain distinct adoption pathways and vendor strategies across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics play a central role in shaping the deployment, regulatory acceptance, and commercial strategies for short-read sequencing. In the Americas, robust research infrastructure, wide availability of clinical trial networks, and relatively mature reimbursement pathways support rapid translation of sequencing into diagnostics and therapeutics discovery. The concentration of biotech hubs and large-scale sequencing centers creates demand for both high-throughput instruments and sophisticated bioinformatics services, while procurement practices emphasize service-level guarantees and long-term vendor partnerships.

In Europe, Middle East & Africa, regulatory diversity and varying levels of infrastructure investment create a heterogeneous adoption landscape. Western European markets often prioritize hospital integration and clinical validation pathways, whereas emerging markets in the region show strong academic research uptake and increasing interest from public health programs. Strategic partnerships that include training, local technical support, and adaptive pricing models accelerate broader adoption across these varied contexts. Regulatory harmonization efforts and cross-border research consortia are progressively smoothing integration challenges.

In Asia-Pacific, rapid capacity building, government-supported genomics initiatives, and strong manufacturing capabilities are accelerating both demand and local supply. High-throughput sequencing applications tied to population-scale studies and genomics-driven drug discovery are prominent, and regional providers are increasingly competitive on cost, localization, and scale. Across all regions, geographic considerations inform choices about inventory buffers, training programs, and deployment models, and vendors that tailor offerings to regional needs and policy environments gain a strategic advantage.

How leading companies combine instrument innovation, consumable reliability, and analytics services to build integrated platforms and durable customer relationships

Companies at the forefront of short-read sequencing are differentiating through integrated platform capabilities, expanded service offerings, and strategic partnerships that accelerate clinical adoption. Leading instrument manufacturers continue to iterate on throughput, run-time, and automation features, while reagent and consumable producers focus on lot-to-lot consistency, supply chain transparency, and streamlined workflows that reduce operator dependency. Service and software providers that deliver validated pipelines, interpretive reporting, and secure data management are becoming indispensable, especially for clinical and regulatory use cases.

Competitive positioning now extends beyond hardware to include recurring revenue models, cloud-enabled analytics, and co-development arrangements with large academic centers and pharmaceutical customers. As a result, some vendors are bifurcating their business models to serve high-throughput central laboratories while offering simplified benchtop solutions for point-of-care and smaller research settings. Partnerships with contract research organizations and localized distribution networks help many companies scale internationally while maintaining compliance and technical support standards.

Strategic acquisitions, collaborative development agreements, and investments in manufacturing redundancy are common tactics companies use to secure supply continuity and broaden technological portfolios. Firms that emphasize interoperability, open data standards, and comprehensive customer education programs earn greater trust among institutional buyers and clinical laboratories, which in turn supports deeper long-term relationships and recurring business.

Actionable recommendations for industry leaders to enhance supply resilience, customer-centric offerings, and clinical validation pathways that drive sustained adoption

Industry leaders should prioritize actions that balance near-term operational resilience with long-term strategic positioning. First, strengthening supply chain diversity and establishing regional manufacturing or distribution partnerships will reduce exposure to tariff and logistics volatility while improving service responsiveness. Second, investing in validated, user-friendly workflows-spanning sample prep, run automation, and standardized analytics-will lower the barrier to adoption across clinical and decentralized research settings and accelerate time-to-impact.

Third, building modular business models that offer both capital acquisition and subscription-based reagent or software services creates more predictable revenue streams and aligns vendor incentives with customer success. Fourth, companies should deepen collaborations with clinical networks and regulatory bodies to co-develop validation datasets and diagnostic use cases, thereby reducing time-to-market for clinical assays. Fifth, focusing on data interoperability, privacy-compliant cloud frameworks, and interpretive reporting will make sequencing outputs actionable for clinicians and researchers alike.

Finally, leaders must invest in workforce enablement through training, certification, and localized technical support to ensure customers achieve consistent, high-quality results. By combining operational robustness with customer-centric product development and collaborative validation pathways, organizations can capture greater strategic value from the expanding role of short-read sequencing in science and medicine.

Transparent research methodology combining primary interviews, secondary source triangulation, and cross-segmentation analysis to ensure reliable and actionable insights

The research underpinning this analysis integrates qualitative and quantitative approaches to ensure robust, reproducible insights. Primary research included structured interviews with executives, laboratory directors, procurement leads, and technical specialists across academic, clinical, and commercial institutions. These interviews provided firsthand perspectives on adoption drivers, validation requirements, procurement behaviors, and operational pain points, which informed thematic synthesis and scenario analysis.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, company technical specifications, white papers, and public disclosures that describe technological capabilities, workflow performance metrics, and deployment case studies. Comparative evaluation of these sources enabled triangulation of product characteristics, application suitability, and commercial strategies. Where appropriate, supplier documentation and open data repositories were cross-referenced to validate performance claims and identify reproducibility considerations.

Analytical methods included cross-segmentation mapping to reveal alignment between product offerings and application needs, sensitivity assessments to explore the operational impact of policy and supply chain shifts, and stakeholder impact mapping to prioritize recommendations. Rigorous quality controls-such as interview validation, source corroboration, and iterative peer review-were applied throughout the research lifecycle to maintain accuracy and practical relevance for decision-makers.

Concluding synthesis that connects technological maturity, operational resilience, and collaborative strategies to realize the value of short-read sequencing

In conclusion, short-read sequencing stands at the intersection of mature technical capability and expanding application breadth, offering a pragmatic balance between accuracy, throughput, and established analytical ecosystems. The technology's continued refinement in reagents, instrument automation, and data analysis is broadening its applicability from core research laboratories to clinical and industrial settings. Simultaneously, external forces such as regulatory evolution and tariff-driven supply chain adjustments are prompting stakeholders to adopt more resilient procurement and validation practices.

The cumulative picture is one of steady integration: vendors that deliver interoperable, validated workflows and resilient supply strategies will realize greater adoption, while customers that prioritize standardized processes and training will extract more consistent value from their investments. Strategic partnerships across manufacturers, service providers, and end users accelerate the translation of sequencing capabilities into actionable insights for diagnostics, drug discovery, and public health surveillance. By aligning technological choices with operational realities and regulatory requirements, organizations can harness short-read sequencing to advance scientific goals and clinical outcomes.

This document synthesizes the core dynamics shaping the ecosystem and outlines practical steps for stakeholders seeking to optimize technology selection, supply continuity, and application deployment in the near term and beyond.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Short-read Sequencing Market, by Product

• 8.1. Consumables
  • 8.1.1. Flow Cells & Reagents
  • 8.1.2. Library Prep Kits
• 8.2. Instruments
  • 8.2.1. Benchtop Sequencers
  • 8.2.2. High-Throughput Sequencers
• 8.3. Software & Services
  • 8.3.1. Bioinformatics Services
  • 8.3.2. Data Analysis Software

9. Short-read Sequencing Market, by Technology

• 9.1. Semiconductor Sequencing
  • 9.1.1. Ion Proton
  • 9.1.2. Ion Torrent PGM
• 9.2. Sequencing Ligation
• 9.3. Sequencing Synthesis

10. Short-read Sequencing Market, by End User

• 10.1. Academic & Research Institutes
• 10.2. Contract Research Organizations
• 10.3. Hospitals & Diagnostic Labs
• 10.4. Pharma & Biotech Companies

11. Short-read Sequencing Market, by Application

• 11.1. Epigenomics
  • 11.1.1. Chromatin Accessibility Analysis
  • 11.1.2. DNA Methylation Analysis
• 11.2. Genomics
  • 11.2.1. Resequencing
  • 11.2.2. Targeted Sequencing
  • 11.2.3. Whole Genome Sequencing
• 11.3. Metagenomics
• 11.4. Transcriptomics

12. Short-read Sequencing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Short-read Sequencing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Short-read Sequencing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Short-read Sequencing Market

16. China Short-read Sequencing Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Agilent Technologies, Inc.
• 17.6. BGI Genomics Co., Ltd.
• 17.7. Bio-Rad Laboratories, Inc.
• 17.8. Danaher Corporation
• 17.9. Eppendorf SE
• 17.10. Eurofins Scientific SE
• 17.11. F. Hoffmann-La Roche Ltd
• 17.12. GE HealthCare Technologies Inc.
• 17.13. Genewiz, Inc.
• 17.14. Hamilton Company
• 17.15. Illumina, Inc.
• 17.16. Macrogen, Inc.
• 17.17. Novogene Co., Ltd.
• 17.18. Oxford Nanopore Technologies plc
• 17.19. Pacific Biosciences of California, Inc.
• 17.20. PerkinElmer, Inc.
• 17.21. Psomagen, Inc.
• 17.22. Qiagen N.V.
• 17.23. Takara Bio Inc.
• 17.24. Thermo Fisher Scientific Inc.